News | July 20, 2008

RT for Rare Breast Cancer May Lower Recurrence Rate

July 20, 2008 - Patients with a rare type of breast cancer may benefit from receiving radiation therapy in addition to surgery to prevent recurrence, according to a study in the July issue of the International Journal of Radiation Oncology Biology Physics, the official journal of the American Society for Therapeutic Radiology and Oncology.

Phyllodes tumors are rare breast tumors that develop in the connective tissue of the breast, as opposed to more common carcinomas, which develop in the ducts or lobules of the breast. Most patients are treated for phyllodes tumors with either a lumpectomy or mastectomy, with only a small fraction of patients receiving radiation therapy.

Traditionally, adjuvant radiation therapy is recommended for cancer patients with local recurrence risks of 15 percent or greater, but the value of adjuvant radiation therapy has not been extensively studied for phyllodes tumors because they are so rare.

Researchers at the Division of Radiation Oncology, Department of Medical Physics, and Department of General and Oncologic Surgery at City of Hope National Medical Center in Duarte, CA, sought to determine the local recurrence rates of phyllodes tumors based on tumor size and the type of surgery performed and whether adjuvant radiation therapy should be considered as a treatment for some phyllodes tumor patients to reduce their local recurrence rate.

“Typically these tumors are treated well by surgery alone. However, local recurrences are not uncommon,” said Richard Pezner, M.D., lead author of the study and a radiation oncologist at City of Hope National Medical Center.

The study authors reviewed records of 478 patients with malignant phyllodes tumors who were treated between March 1964 and August 2005. The records came from the IMPAC National Oncology Database, which consists of tumor registries from 130 hospitals.

The researchers found that the risk of local recurrence for phyllodes tumors was related to tumor size and the type of surgery received. They determined that adjuvant radiation therapy should be evaluated for phyllodes tumor patients who received lumpectomies for tumors at least 2 centimeters in size or a mastectomy for tumors at least 10 centimeters in size to reduce the risk of recurrence.

Source: ASTRO (American Society for Therapeutic Radiology & Oncology)

For more information: www.astro.org

Related Content

Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
News | Brachytherapy Systems | June 07, 2018
IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
Raysearch RayStation
Feature | Radiation Therapy | June 05, 2018 | By Melinda Taschetta-Millane
Treatment planning systems are at the heart of r...
Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer
News | Proton Therapy | May 31, 2018
Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at...
More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage
News | Proton Therapy | May 25, 2018
The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial...
News | Treatment Planning | May 24, 2018
Daniela Schmitt, Ph.D., took top honors in the overall category of the 2018 TROG Plan Study: Stereotactic Radiosurgery...
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
Mercy Signs Multi-System, Multi-Hospital Agreement for Accuray Radiotherapy Systems
News | Radiation Therapy | May 16, 2018
Accuray Inc. signed a multi-system, multi-hospital agreement with Mercy for the acquisition of Accuray Radixact and...
Overlay Init